Atlas Legacy Advisors’s Pfizer PFE Stock Holding History

Atlas Legacy Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,675	Closed	-$247K	–	211
2025 Q3	$247K	Buy	+9,675	New	+$239K	0.05%	181

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Atlas Legacy Advisors's PFE Position: Q4 2025 in Review

Atlas Legacy Advisors sold out of Pfizer (PFE) in Q4 2025, closing a stake of 9,675 shares — an estimated $247K sold.

Atlas Legacy Advisors first reported a position in PFE in Q3 2025 and held it in 1 quarter. The position peaked at $247K in Q3 2025. 2,915 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

Atlas Legacy Advisors reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
Atlas Legacy Advisors sold 9,675 Pfizer shares in Q4 2025, an estimated $247K.
Atlas Legacy Advisors first reported a position in Pfizer in Q3 2025 and held it in 1 quarter.
Atlas Legacy Advisors's Pfizer position peaked at $247K in Q3 2025.
2,915 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Atlas Legacy Advisors's 13F filing for Q4 2025, filed 29 Jan 2026.